WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: nano2-2, Insurance companies are most likely to help regulate nanotechnology. therefore (ArgScheme: modus ponens) New premiums will be created to asses the risk of creating and selling nanotechnology., If insurance companies are most likely to help regulate nanotechnology, then new premiums will be created to asses the risk of creating and selling nanotechnology. therefore (ArgScheme: modus ponens) New premiums will be created to asses the risk of creating and selling nanotechnology., No new tests focusing on nanoparticles are run on these products. therefore (ArgScheme: modus ponens) The FDA does not know how nanoparticles will effect the body., If cosmetic products are not pre-market screened, then NSPs used in cosmetic products can be produced without restrictions. therefore (ArgScheme: modus ponens) NSPs used in cosmetic products can be produced without restrictions., The FDA has no rules or regulations on products that use nanoparticles. therefore (ArgScheme: modus ponens) No new tests focusing on nanoparticles are run on these products., If no new tests focusing on nanoparticles are run on these products, then the FDA does not know how nanoparticles will effect the body. therefore (ArgScheme: modus ponens) The FDA does not know how nanoparticles will effect the body., Nanotechnology is growing very rapidly and we do not understand all the effects and problems that can occur by using it. therefore (ArgScheme: modus ponens) There needs to be more regulation on using nanoparticles., If nanotechnology is often referenced with asbestos, then more regulation will be placed on producing and selling nanotechnology. therefore (ArgScheme: modus ponens) More regulation will be placed on producing and selling nanotechnology., The private market needs to regulate nanotechnology. therefore (ArgScheme: modus ponens) Insurance companies are most likely to help regulate nanotechnology., The government does not wish to regulate nanotechnology production and selling. therefore (ArgScheme: modus ponens) The private market needs to regulate nanotechnology., If the private market needs to regulate nanotechnology, then insurance companies are most likely to help regulate nanotechnology. therefore (ArgScheme: modus ponens) Insurance companies are most likely to help regulate nanotechnology., If the government does not wish to regulate nanotechnology production and selling, then the private market needs to regulate nanotechnology. therefore (ArgScheme: modus ponens) The private market needs to regulate nanotechnology., Large doses of carbon tubes were injected into the rats, and this large dose is probably what caused it. Smaller amounts are safer. defeats If rats developed inflamed lungs when carbon nanotubes were injected, then nanotechnology can be harmful to our health., If larger nanoparticles are prone to cause more health problems, especially in the lungs, then small nanoparticles should be used. therefore (ArgScheme: modus ponens) Small nanoparticles should be used., If the FDA has no rules or regulations on products that use nanoparticles, then no new tests focusing on nanoparticles are run on these products. therefore (ArgScheme: modus ponens) No new tests focusing on nanoparticles are run on these products., Rats developed inflamed lungs when carbon nanotubes were injected. therefore (ArgScheme: modus ponens) Nanotechnology can be harmful to our health., Nanotechnology is often referenced with asbestos. therefore (ArgScheme: modus ponens) More regulation will be placed on producing and selling nanotechnology., If the TSCA only regulates mixtures of voume greater than the amount of nanoparticles produced, and it needs substantial evidence to prove that products are causing harm, then the TSCA cannot nanotechnology. therefore (ArgScheme: modus ponens) the TSCA cannot nanotechnology., The TSCA only regulates mixtures of voume greater than the amount of nanoparticles produced, and it needs substantial evidence to prove that products are causing harm. therefore (ArgScheme: modus ponens) the TSCA cannot nanotechnology., Cosmetic products are not pre-market screened. therefore (ArgScheme: modus ponens) NSPs used in cosmetic products can be produced without restrictions.